Case Study: Eisai Partners With Swedish Startup BioArctic In Search Of Cure For Alzheimer’s Disease (Part 2 Of 2)
This article was originally published in PharmAsia News
Executive Summary
Eisai has taken an aggressive approach in seeking out the right partners to fill out its pipelines. The company's partnership with Swedish startup BioArctic to develop a drug for Alzheimer's disease is no exception. Eisai and BioArctic discussed the beginnings of their partnership in the first part of this case study (PharmAsia News, Aug. 6, 2008). This second section discusses in greater detail why the companies view the partnership as a success and what each has brought to the other.
You may also be interested in...
Eisai’s Ontak sBLA Granted U.S. FDA Approval
TOKYO - U.S. FDA granted full approval to Eisai's biologic Ontak (denileukin) for intravenous injection for treating a recurrent type of lymph node cancer, cutaneous T-cell lymphoma in patients whose malignant cells express the CD25 component of the interleukin-2 receptor
Eisai’s Ontak sBLA Granted U.S. FDA Approval
TOKYO - U.S. FDA granted full approval to Eisai's biologic Ontak (denileukin) for intravenous injection for treating a recurrent type of lymph node cancer, cutaneous T-cell lymphoma in patients whose malignant cells express the CD25 component of the interleukin-2 receptor
Bayer Signs Licensing Agreement With Nagasaki University For Alzheimer’s Diagnosis Compounds
TOKYO - Bayer Schering Pharma signed a licensing agreement for worldwide development and distribution of diagnostic radioactive tracers made from compounds developed by Nagasaki University to detect Alzheimer's disease, Morio Nakayama, head of research, told PharmAsia News Sept. 17